Method for detecting HMWK (high molecular weight kininogen) defect without disease diagnosis
Through calcium recalcium test and threshold calculation, the problem of difficulty in detecting HMWK defects in the prior art is solved, and the accurate judgment of HMWK defects in sample plasma is achieved, and the accuracy and safety of coagulation function diagnosis is improved.
Patent Information
- Application Number
- CN202411015537.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to accurately detect high molecular weight kinin HMWK defects, resulting in the inability to clarify the diagnosis and treatment instructions for coagulation abnormalities.
Using the calcium recombination test method, sample plasma and APTT reagent were added to the coagulation analysis instrument, and different incubation times were set. The calcium recombination test curve characteristics and the maximum number of seconds decreased and increased percentages were calculated, and the threshold was set to distinguish HMWK defects from other factor defects. , realize the judgment of HMWK defects.
It provides a simple, accurate and low-cost method that can detect HMWK defects without using plasma, improves diagnostic accuracy in the field of coagulation function and avoids unnecessary hemostasis treatment.
Smart Images

Figure CN118937705A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomolecule detection, and in particular to a method for detecting high molecular weight kininogen HMWK deficiency for the purpose of non-disease diagnosis. Background Art
[0002] Kininogen is the precursor of kinins such as bradykinin and kallikrein. There are two types of human kininogens, high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK), which are splice variants. HMWK is a protein secreted by the liver and kidneys, which is involved in initiating blood coagulation. HMWK mainly acts as a cofactor of coagulation factor XII (FXII), and is a preferred substrate for bradykinin generation mediated by plasma kallikrein (pKal), and is an important part of the kinin release system. It promotes the activation of FXII, promotes the conversion of kallikreinogen (PK) to pKal, and can accelerate the activation of FXII by pKal, and participates in the contact activation of the intrinsic coagulation pathway. The coagulation factors of the endogenous coagulation pathway of the human body include FVIII, FIX, FXI, FXII, PK and HMWK.
[0003] The activated partial thromboplastin time (APTT) assay is the most commonly used sensitive screening test in clinical practice to reflect the coagulation activity of the intrinsic coagulation system. It is widely used to screen for defects in intrinsic pathway coagulation factors, such as coagulation factors VIII, IX, XI, and XII. It can also be used for laboratory monitoring of heparin anticoagulation therapy. The APTT test is a test that uses multiple coagulation factors. Starting from the contact factor on the phospholipid catalytic surface in the presence of an activator, the coagulation factor catalytic cascade reaction is gradually activated, eventually activating thrombin in the plasma, and then converting fibrinogen into fibrin to form a plasma clot, and obtaining the coagulation time. If the APTT time result exceeds the reference range of the normal population, it can be considered that the following situations may occur in the sample plasma:
[0004] (1) The presence of lupus anticoagulant or other antiphospholipid antibodies in the patient's plasma;
[0005] (2) Lack or deficiency of endogenous factors FVIII, FIX, FXI, FXII, PK, and HMWK;
[0006] (3) the presence of coagulation factor inhibitors;
[0007] In clinical practice, once an abnormal increase in the APTT test results is encountered, it is necessary to consider the lack of endogenous factors or the presence of coagulation factor inhibitors. If this possibility exists, it means that the coagulation function is abnormal and the patient will have a higher risk of bleeding. In the case of endogenous factor deficiency, only when the activity of the three coagulation factors FVIII (hemophilia A), FIX (hemophilia B), and factor XI is determined to be low can it be determined that there is a risk of bleeding. In clinical practice, prothrombin complex, fresh frozen plasma, cryoprecipitate, VIIa and other preparations are needed to prevent bleeding in such patients or to stop bleeding in patients. However, as a preliminary screening test, the APTT test has an abnormally elevated result and cannot specifically indicate which of the above reasons exists in the sample plasma.
[0008] When the sample plasma is tested using the APTT test, and both the immediate APTT correction test and the incubation APTT correction test are corrected, if the APTT result is abnormally elevated, the sample PT (prothrombin time) result is within the normal reference range, and the presence of anticoagulants such as heparin in the plasma is excluded (excluding the patient's use of anticoagulants such as heparin for treatment), it is necessary to consider whether there is a deficiency of the four endogenous factors FVIII, FIX, FXI, and FXII, as well as a deficiency of PK and HMWK, and there is no need to consider other factors that cause abnormally high APTT results. (This method is detailed in the 2021 edition of the "Chinese Expert Consensus on the Operational Procedure and Interpretation of Results of the Correction Test for Prolonged Activated Partial Thromboplastin Time Mixed Plasma", the flowchart is as follows Figure 1 shown.)
[0009] In clinical practice, if there are congenital defects in the three coagulation factors FXII, HMWK, and PK in human plasma, it will not actually cause bleeding symptoms. If there is a deficiency of FVIII, FIX, or FXI in the sample plasma, the patient will be at greater risk of bleeding, and clinical measures need to be taken to prevent the patient's bleeding risk in advance. However, if it is confirmed that there is an HMWK deficiency in the sample plasma, even if the APTT test results show an abnormally high value, it can be determined that the patient does not need special treatment in the field of coagulation function, nor does it need to use hemostatic agents to prevent bleeding in the patient.
[0010] For the degree of coagulation factor deficiency, it is necessary to use single-factor-deficient plasma combined with APTT reagent to measure the activity of coagulation factors on a fully automatic coagulation analyzer, but general medical laboratories usually do not carry out coagulation factor activity measurement projects, but use APTT tests for evaluation. Without using the method of coagulation factor activity measurement, how to identify HMWK-deficient plasma is an existing technical problem. Therefore, the present invention aims to provide a method that can effectively, simply and accurately detect HMWK deficiency. It can provide clearer instructions for the treatment of clinical coagulation function. Summary of the invention
[0011] 1. Technical issues to be solved
[0012] In view of the deficiencies of the prior art, the present invention provides a method for detecting high molecular weight kininogen HMWK deficiency for the purpose of non-disease diagnosis.
[0013] (II) Technical solution
[0014] To achieve the above objectives, the present invention is implemented through the following technical solutions:
[0015] A method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes, the method comprising the following steps:
[0016] (1) Automatically adding sample plasma into a reaction cup on a coagulation analysis instrument;
[0017] (2) Add APTT reagent to the sample plasma, set different incubation times, and incubate them together at 37°C;
[0018] (3) Calcium chloride is added to trigger the coagulation process. Blood coagulation takes time, and the recalcification test results are obtained in seconds at different incubation times;
[0019] (4) The incubation time is taken as the horizontal axis and the number of seconds of the recalcification test is taken as the vertical axis to obtain the recalcification test curve; the test data are calculated and analyzed based on the curve.
[0020] Furthermore, the PT result of the sample plasma was within the normal reference range, and the APTT result was abnormally elevated, drug contamination such as heparin had been ruled out, and the APTT correction test had been completely corrected.
[0021] Furthermore, the different incubation times in step (2) are set to use the instrument manufacturer's parameters as the original incubation time, and then set the incubation time to 5 min, 10 min, 15 min, 20 min, and 30 min.
[0022] Furthermore, the recalcification test curve in step (4) shows the typical characteristics of the unique recalcification test curve of HMWK-deficient plasma, which first drops sharply, reaches the lowest point, and then rises sharply. Based on the characteristics of this curve, it can be judged whether there is HMWK deficiency in the sample plasma.
[0023] Furthermore, the calculation and analysis method in step (4) is specifically to calculate the percentage rate of decrease of the maximum number of seconds in the recalcification test and the percentage rate of increase of the maximum number of seconds in the recalcification test;
[0024] Furthermore, the percentage rate of decrease of the maximum number of seconds of the recalcification test = (the number of seconds of the APTT test result under the original incubation time - the minimum number of seconds of the recalcification test) / the number of seconds of the APTT test result under the original incubation time.
[0025] Furthermore, the percentage increase rate of the maximum number of seconds in the recalcification test = (the number of seconds in the recalcification test at an incubation time of 30 minutes - the minimum number of seconds in the recalcification test) / the minimum number of seconds in the recalcification test.
[0026] Furthermore, the method for determining the HMWK deficiency in the sample plasma according to the curve characteristics is as follows:
[0027] (1) The contact defect group was defined as HMWK deficiency and FXII deficiency, and the non-contact defect group was defined as FVIII deficiency and FIX deficiency; a threshold A was set to distinguish the contact defect group from the non-contact defect group; threshold A = 12.15% ╳ 2 = 24.30%;
[0028] (2) Threshold B is set to distinguish HMWK defect from FXII defect; threshold B = 10.05% x 3 = 30.15%;
[0029] (3) Sequence comparison D1 is performed using threshold A to determine whether it is a contact defect group; if sequence comparison D1 is a contact defect group, sequence comparison D2 is performed using threshold B to determine whether it is a HMWK defect;
[0030] Among them, sequence comparison D1: threshold A is used to distinguish the contact defect group from the other factor deficiency group; specifically, if the percentage of the maximum seconds of the recalcification test decreases > 24.30%, it is judged as the contact defect group; if the percentage of the maximum seconds of the recalcification test decreases ≤ 24.30%, it is judged as the non-contact defect group;
[0031] Sequence comparison D2: Threshold B is used to judge HMWK defect; specifically, if the maximum percentage increase in seconds of the recalcification test is >30.15%, it is judged as HMWK defect; if the maximum percentage increase in seconds of the recalcification test is ≤30.15%, it is judged as non-HMWK defect.
[0032] For normal people, the APTT test seconds are within the normal reference range (26-40s), and generally there is no need to identify HMWK deficiency; only when the APTT is an obviously abnormally high value, it is necessary to consider screening for HMWK deficiency. Since FXII, PK, and HMWK are all contact factors, when they are deficient, after the human plasma APTT reagent is co-incubated at 37°C, due to the lack of specific contact factors for the initial coagulation reaction, after different incubation time reactions, after adding calcium chloride, the plasma will coagulate within a certain period of time. This coagulation time is the result of the recalcification test with data characteristics. Connecting these result points in a two-dimensional graph (with incubation time as the horizontal axis and recalcification test result seconds as the vertical axis) will show specific curve characteristics and numerical changes. The curve characteristics of HMWK-deficient plasma will show the typical characteristics of a sharp drop first, reaching the lowest point, and then a sharp rise.
[0033] (III) Beneficial effects
[0034] Currently, FXII deficiency plasma and APTT reagent can be used to measure factor activity for FXII deficiency or FXII defect, but there is no simple and convenient method for HMWK deficiency. The detection method for HMWK deficiency relies on gene sequencing or HMWK activity detection kit. The HMWK activity detection kit requires HMWK-deficient plasma. In the presence of HMWK-deficient plasma, a calibration curve is prepared in combination with commercial APTT reagent, and then the plasma sample is measured to obtain the HMWK activity test result.
[0035] The present invention provides a method for detecting high molecular weight kininogen HMWK deficiency without using deficient plasma. The method specifically comprises: performing a recalcification test on sample plasma, setting different incubation time parameters, and obtaining a recalcification test curve with different incubation times as the horizontal coordinate and the number of seconds of the recalcification test as the vertical coordinate. We obtain a unique recalcification test curve characteristic of HMWK deficiency (showing the typical characteristics of first a sharp drop, reaching the lowest point, and then a sharp rise). Based on the curve characteristics and related data analysis, it is possible to judge whether the sample plasma has HMWK deficiency.
[0036] The present invention sets different incubation time parameters, especially innovatively sets a 15-minute incubation time parameter, so that the recalcification curve shows the unique characteristics of the HMWK defect sample. At the same time, we also provide a calculation method for the maximum percentage rate of decrease in the number of seconds in the recalcification test and the maximum percentage rate of increase in the number of seconds in the recalcification test, making the method of the present invention using the recalcification test to detect HMWK defects more complete and accurate.
[0037] Compared with the methods of coagulation factor activity reagent detection and gene sequencing, the method for detecting high molecular weight kininogen HMWK deficiency provided by the present invention is simple to operate, low in cost, and can quickly and accurately detect HMWK deficiency in sample plasma. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 Corrected APTT test results and their clinical significance.
[0039] Figure 2 Flowchart of the method for detecting high molecular weight kininogen HMWK deficiency.
[0040] Figure 3 This is the recalcification test curve of the plasma sample of Case 1 on ACL TOP 700.
[0041] Figure 4 This is the recalcification test curve of the plasma sample of Case 2 on ACL TOP 750.
[0042] Figure 5 This is the recalcification test curve of the plasma sample of Case 3 on ACL TOP 700.
[0043] Figure 6 This is the recalcification test curve of the plasma sample of Case 4 on ACL TOP 700.
[0044] Figure 7 This is the recalcification test curve of the plasma sample of Case 5 on ACL TOP 700. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0046] Example 1
[0047] Calculation of the maximum seconds decrease percentage rate threshold A and the maximum seconds increase percentage rate threshold B of the recalcification test. Plasma samples collected from January 2023 to June 2024, including 6 FXII deficiency samples, 8 VIII deficiency samples, 5 FIX deficiency samples and 2 FXI deficiency samples, were used for recalcification test, and the maximum seconds decrease percentage rate and the maximum seconds increase percentage rate of the recalcification test were obtained. The results are shown in Table 1.1.
[0048] Table 1.1 Recalcification test data of 21 samples
[0049]
[0050] * indicates no descending and ascending characteristics
[0051] The contact defect group was defined as HMWK deficiency and FXII deficiency, and the non-contact defect group was defined as FVIII deficiency and FIX deficiency. The maximum percentage decrease in seconds of the recalcification test was used to distinguish the contact defect group and the non-contact defect group. The threshold A = (the average value of the maximum percentage decrease in seconds of the recalcification test in the non-contact defect group) × 2;
[0052] The maximum percentage increase rate of the recalcification test in seconds threshold B is used to distinguish HMWK deficiency from FXII deficiency. Threshold B = the average value of the maximum percentage increase rate of the recalcification test in seconds of the FXII deficiency group × 3;
[0053] Threshold A = 12.15% x 2 = 24.30%
[0054] Threshold B = 10.05% x 3 = 30.15%
[0055] Sequence comparison D1: Threshold A is used to distinguish the contact defect group from the other factor deficiency groups. If the percentage of the maximum seconds decreased in the recalcification test is >24.30%, it is judged as the contact defect group; if the percentage of the maximum seconds decreased in the recalcification test is ≤24.30%, it is judged as the non-contact defect group;
[0056] After performing sequence comparison D1, it is determined to be a contact defect group, and then sequence comparison D2 is performed;
[0057] Sequence comparison D2: Threshold B is used to judge HMWK defect. If the maximum percentage increase in the second of the recalcification test is >30.15%, it is judged as HMWK defect; if the maximum percentage increase in the second of the recalcification test is ≤30.15%, it is judged as non-HMWK defect.
[0058] The flowchart of the method for detecting high molecular weight kininogen HMWK defects provided by the present invention is as follows Figure 2 shown.
[0059] The following further illustrates a method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes provided by the present invention based on 5 clinical cases.
[0060] Example 2
[0061] Case 1: A 49-year-old female patient complained of dizziness and fatigue for one month and was found to have abnormal coagulation function for one week.
[0062] Current medical history: dizziness and fatigue occurred without obvious cause one month ago. Blood routine test at a local hospital: white blood cell count 5.83×10 9 / L, red blood cell count 4.07×10 12 / L, hemoglobin 102g / L, platelets 337×10 9 / L, now for further diagnosis and treatment, the outpatient department admitted him to the hospital with the title of "Hemophilia?" Since the onset of the disease, his appetite has been normal, his sleep has been poor, his bowel movements and urination have been normal, and his weight has not decreased.
[0063] Past medical history: general physical condition, hypertension for 1 year, no history of surgery, trauma, or blood transfusion.
[0064] Marital and reproductive history: Married, with 2 sons and 1 daughter, and husband is in good health.
[0065] Family history: Father is alive, mother is deceased. Brothers, sisters, and children are in good health, have no similar diseases to the patient, and have no family history of genetic diseases.
[0066] Physical examination: normal development, good nutrition, independent posture, free expression, cooperative in physical examination. No rash or subcutaneous hemorrhage on skin or mucous membranes.
[0067] Admission diagnosis: 1. Hemophilia? 2. Iron deficiency anemia 3. Hypertension
[0068] After admission, the results of coagulation-related tests were as follows:
[0069] Table 2.1 Routine coagulation test results of case 1 patient
[0070]
[0071]
[0072] The patient's PT result was normal, but the APTT was significantly prolonged. A corrective test was needed to determine whether it was a lack of endogenous factors. The results are shown in Table 2.2.
[0073] Table 2.2 APTT correction test for case 1 patient
[0074]
[0075] Since PT was normal and the APTT correction test was able to completely correct the abnormal increase in APTT due to endogenous factor deficiency, we conducted a recalcification test on this sample plasma. We set the original APTT, 5min, 10min, 15min, 20min, and 30min incubation time gradients to obtain the recalcification test results in seconds at different incubation times and draw the recalcification test curve. The results are shown in the figure. Figure 3 shown.
[0076] The recalcification test curve of the patient's plasma in Case 1 on ACL TOP 700 showed a typical feature of a sharp drop, reaching the lowest point at 15 minutes, and then rising sharply.
[0077] We calculated the percentage of decrease in the maximum seconds of the recalcification test and the percentage of increase in the maximum seconds of the recalcification test for patient 1 as follows:
[0078] Table 2.3 Maximum seconds decrease ratio and maximum seconds increase ratio of the recalcification test in case 1 patient
[0079] Maximum seconds drop rate Maximum seconds increase rate 52.7% 47.0%
[0080] Threshold A = 12.15% x 2 = 24.30%;
[0081] Threshold B = 10.05% x 3 = 30.15%;
[0082] Sequence comparison D1: 52.7%>24.30%, judged as contact defect group. Continue with sequence comparison D2.
[0083] Sequence comparison D2: 47.0%>30.15%, indicating that the patient has HMWK deficiency.
[0084] Other coagulation-related items were measured for Case 1, and the results are as follows:
[0085] Table 2.4 Results of other blood coagulation tests in case 1
[0086] Serial number English name Chinese name Project Results Reference interval unit 1 AT3 Antithrombin-III 77.00 83-128 % 2 PC Protein C activity 97.00 70-140 % 3 PS Protein S activity 59.60 76-135 % 3 dV Lupus anticoagulant screening ratio 0.93 0.92-1.11 4 dV Lupus anticoagulant confirmed ratio 1.05 0.92-1.11 5 TR Lupus anticoagulant normalized ratio 0.89 0-1.2 6 II Factor II activity 87.20 50-150 % 7 V Factor V activity 98.30 62-139 % 8 VII Factor VII activity 67.40 50-129 % 9 VIII Factor VIII activity 154.30 50-150 % 10 IX Factor IX activity 84.40 65-150 % 11 X X-Factor Activity 73.40 50-150 % 12 XI Factor XI activity 66.20 65-150 % 13 XII Factor XII activity 78.40 50-150 % 14 VWF Activity VWF activity 94.70 40.3-163.4 %
[0087] There is no deficiency of endogenous coagulation factors FVIII, FIX, FXI, and FXII.
[0088] The final genetic test results of Case 1 patient proved that this was a patient with HMWK deficiency (the results are shown in Table 2.5).
[0089] Table 2.5 Genetic test results of case 1 patient
[0090] Gene Nucleotide changes Amino acid changes Heterozygosity KNG1 c.1744C>T <![CDATA[P.Gln582 * ]]> Homozygous
[0091] Combined with the coagulation factor activity determination and gene detection results, it is shown that the method provided by the present invention can simply and accurately detect whether there is HMWK deficiency in the sample plasma.
[0092] Example 3
[0093] Case 2: The patient was a 33-year-old female who was admitted to the hospital with the chief complaint of “sudden headache and vomiting for 15 days”.
[0094] Current medical history: The patient reported that he had a sudden persistent headache with nausea and vomiting 15 days ago without obvious cause. The headache was centered in the bilateral temporal area, and the vomitus was gastric contents. He had no symptoms such as impaired consciousness, dizziness, blurred vision, and weakness in the limbs. He went to a local hospital for treatment. MRI of the head showed a mass in the sellar region (not reported). After conservative treatment, the above symptoms were relieved. He came to our hospital for further treatment.
[0095] Past medical history: denied chronic diseases such as hypertension, diabetes, coronary heart disease, history of infection, history of surgery, history of blood transfusion, and history of food or drug allergies.
[0096] Marital and reproductive history: Married, with 2 sons and 1 daughter, all healthy.
[0097] Family history: Father is healthy, mother is healthy, 1 brother and 1 sister are healthy, and there is no history of family genetic diseases.
[0098] Physical examination: normal development, clear consciousness, independent body position, normal facial and expression, cooperative examination. Skin and mucous membranes have normal color, no rash, no petechiae, no purpura.
[0099] Admission diagnosis: space-occupying pituitary tumor in the sellar region?
[0100] In the routine coagulation test results of case 2, the PT was normal, the APTT was abnormally elevated (Table 3.1), reaching 215.0 seconds, and the other items were normal. After excluding factors such as sample quality and the patient's use of anticoagulants, there are several reasons for the patient's APTT prolongation: (1) the presence of lupus anticoagulant or other antiphospholipid antibodies in the patient's plasma; (2) lack of intrinsic factors; (3) the presence of coagulation factor inhibitors.
[0101] Table 3.1 Routine coagulation test results of case 2 patients
[0102] Serial number English name Project Results symbol Reference value unit 1 PT 10.1 8.8-13.6 Second 2 PT-INR 0.93 0.8-1.6 3 APTT 215.0 ↑↑ 26-40 Second 4 FIB 3.26 2-4 g / L 5 TT 13.9 10-18 Second 6 D-Dimer 0.097 0-0.3 mg / L
[0103] The patient's PT result is normal, and the APTT is significantly prolonged. A correction test is needed to determine whether it is a lack of endogenous factors. The results are shown in Table 3.2:
[0104] Table 3.2 APTT correction test for case 2 patient
[0105]
[0106]
[0107] Since PT was normal and the APTT correction test was able to completely correct the abnormal increase in APTT due to endogenous factor deficiency, we conducted a recalcification test on this sample plasma. We set the original APTT, 5min, 10min, 15min, 20min, and 30min incubation time gradients to obtain the recalcification test results in seconds at different incubation times and draw the recalcification test curve. The results are shown in the figure. Figure 4 shown.
[0108] The recalcification test curve of the patient's plasma in Case 2 on ACL TOP 750 did not show a significant drop, but reached the lowest point at 15 minutes and then rose sharply, which is a typical feature.
[0109] The maximum seconds increase percentage rate and the maximum seconds decrease percentage rate of the recalcification test were calculated and the results are shown in Table 3.3.
[0110] Table 3.3 The percentage of decrease and increase in the maximum seconds in the recalcification test of case 2 patients
[0111] Maximum seconds drop percentage rate Maximum seconds increase percentage rate 39.9% 10.7%
[0112] Threshold A = 12.15% x 2 = 24.30%;
[0113] Threshold B = 10.05% x 3 = 30.15%;
[0114] Sequence comparison D1: 39.9%>24.30%, judged as contact defect group. Continue with sequence comparison D2.
[0115] Sequence comparison D2: 10.7% ≤ 30.15%, indicating that the patient is not HMWK deficient.
[0116] The results of coagulation factor activity assays for patient Case 2 are shown in Table 3.4. The patient's FXII activity was <1.0%, proving FXII deficiency.
[0117] Table 3.4 Coagulation factor activity determination in case 2 patients
[0118]
[0119]
[0120] Example 4
[0121] Case 3: Female patient, 29 years old, complained of abnormal coagulation function for 3 days
[0122] Current medical history: The patient planned to undergo "in vitro fertilization" 3 days ago. The relevant examinations in this hospital were found to be abnormal in coagulation function, APTT 212.2S, no fever, skin and joint ecchymoses and hematomas, no gingival bleeding, and no similar symptoms in the family history. It is recommended to see a hematologist. Blood routine test showed: white blood cell count 6.94×10 9 / L, hemoglobin 142g / L, platelets 373×10 9 / L, for further diagnosis and treatment, the patient was admitted to the hospital with "abnormal coagulation function" as an outpatient.
[0123] Past history: diagnosed with "eclampsia" in 2014, history of cerebrovascular disease, and other chronic diseases, no history of infection, no history of blood transfusion, denial of food, no history of food allergy, allergic to amoxicillin, and manifested with a systemic rash.
[0124] Marital and reproductive history: Married, healthy spouse, and 1 daughter.
[0125] Family history: The father is healthy, the mother is healthy, and the daughter is healthy. None of them have similar diseases to the patient and there is no history of family genetic diseases.
[0126] Admission diagnosis: abnormal coagulation function. The results of coagulation-related tests are as follows:
[0127] Table 4.1 Routine coagulation test results of case 3 patients
[0128] Inspection items Test results unit Reference range PT[*prothrombin time] 11.5 S 8.8-13.6 PT% [prothrombin time activity] 94 % 70-150 INR [*International Normalized Ratio] 1.04 0.8-1.6 APTT[*Activated Partial Thromboplastin Time] 212.2 S 26-40 Fib[*fibrinogen assay] 2.84 g / L 2-4 TT[*thrombin time] 13.9 S 10-18 D-Dimer 0.04 mg / L 0-0.3
[0129] The PT result of the patient's plasma sample was normal, and the APTT was significantly prolonged. A correction test was needed to determine whether it was a lack of endogenous factors. The results are shown in Table 4.2.
[0130] Table 4.2 APTT correction test for case 3 patient
[0131]
[0132]
[0133] Since PT was normal and the APTT correction test was able to completely correct the abnormal increase in APTT due to endogenous factor deficiency, we conducted a recalcification test on this sample plasma. We set the original APTT, 5min, 10min, 15min, 20min, and 30min incubation time gradients to obtain the recalcification test results in seconds at different incubation times and draw the recalcification test curve. The results are shown in the figure. Figure 5 shown.
[0134] The recalcification test curve of the patient's plasma in Case 3 on ACL TOP 700 showed a typical feature of a sharp drop, reaching the lowest point at 15 minutes, and then rising sharply.
[0135] The percentage rate of increase in the maximum seconds for the recalcification test and the percentage rate of decrease in the maximum seconds for the recalcification test were calculated, and the results are shown in Table 4.3.
[0136] Table 4.3 The percentage of decrease and increase in the maximum seconds in the recalcification test of case 3 patients
[0137] Maximum seconds drop percentage rate Maximum seconds increase percentage rate 53.4% 64.4%
[0138] Threshold A = 12.15% x 2 = 24.30%;
[0139] Threshold B = 10.05% x 3 = 30.15%;
[0140] Sequence comparison D1: 53.4%>24.30%, judged as contact defect group. Continue with sequence comparison D2.
[0141] Sequence comparison D2: 64.4%>30.15%, judged to be HMWK deficiency.
[0142] By sequencing and analyzing the relevant genes of Case 3 patient, the relevant gene mutation sites were detected as follows (as shown in Table 4.4). Considering that the patient's plasma sample has HMWK deficiency, it is consistent with the results of the recalcification test.
[0143] Table 4.4 Genetic test results of case 3 patients
[0144] Gene Nucleotide changes Amino acid changes Heterozygosity KNG1 c.628_629delAA P.Asn210fs Homozygous
[0145] Example 5
[0146] Case 4: Male, 77 years old. Chief complaint: A pulmonary mass was found 2 months ago and he came to the hospital for further treatment.
[0147] Current medical history: The patient's chest CT examination more than 2 months ago showed an irregular nodule in the left upper lobe of the lung, about 19*13mm in size, and a space-occupying lesion to be excluded. No systemic treatment was given. The patient came to our hospital for treatment 1 and a half months ago and underwent percutaneous lung lesion puncture biopsy + microwave ablation. There was no obvious discomfort after the operation.
[0148] Past medical history: hypertension for more than 20 years, diabetes for 8 years, no history of cerebrovascular disease.
[0149] Marital and reproductive history: married at the appropriate age, husband is healthy, and they have 2 sons and 1 daughter.
[0150] Family history: Parents, brothers, and sisters are in good health, have no diseases similar to the patient, and have no history of family hereditary diseases.
[0151] Table 5.1 Results of routine coagulation tests in case 4
[0152] Inspection items Test results unit Reference range PT[*prothrombin time] 11.3 S 8.8-13.6 PT% [prothrombin time activity] 98.5 % 70-150 INR [*International Normalized Ratio] 1.02 0.8-1.6 APTT[*Activated Partial Thromboplastin Time] 208.3 S 26-40 Fib[*fibrinogen assay] 3.92 g / L 2-4 TT[*thrombin time] 15.5 S 10-18 D-Dimer 0.31 mg / L 0-0.3
[0153] The patient's PT result is normal, but the APTT is significantly prolonged. A corrective test is needed to determine whether it is a lack of endogenous factors. The result is shown in 5.2.
[0154] Table 5.2 APTT correction test for case 4 patient
[0155]
[0156]
[0157] Since PT was normal and the APTT correction test was able to completely correct the abnormal increase in APTT due to endogenous factor deficiency, we conducted a recalcification test on this sample plasma. We set the original APTT, 5min, 10min, 15min, 20min, and 30min incubation time gradients to obtain the recalcification test results in seconds at different incubation times and draw the recalcification test curve. The results are shown in the figure. Figure 6 shown.
[0158] The recalcification test curve of the patient's plasma in Case 4 on ACL TOP 700 did not show the typical characteristics of a sharp drop, reaching the lowest point at 15 minutes, and then rising sharply.
[0159] The maximum seconds increase percentage rate and the maximum seconds decrease percentage rate of the recalcification test were calculated. The results are shown in Table 5.3.
[0160] Table 5.3 The percentage of decrease and increase in the maximum seconds in the recalcification test of case 4 patients
[0161] Maximum seconds drop percentage rate Maximum seconds increase percentage rate 35.2% 7.0%
[0162] Threshold A = 12.15% x 2 = 24.30%;
[0163] Threshold B = 10.05% x 3 = 30.15%;
[0164] Sequence comparison D1: 35.2%>24.30%, judged as contact defect group. Continue with sequence comparison D2.
[0165] Sequence comparison D2: 7.0%≤30.15%, judged to be non-HMWK defect.
[0166] By measuring the activity of other coagulation factors in Case 4, it was found that the activity of FXII factor was <1.0%, and the activities of other coagulation factors were normal. This patient was FXII deficient.
[0167] Example 6
[0168] Case 5: Male, 7 years old. Chief complaint: Subcutaneous bleeding and hematoma after bumps and collisions, admitted to hospital for further diagnosis and treatment.
[0169] Family history: Parents are in good health and have no diseases similar to the patient.
[0170] Table 6.1 Routine coagulation test results of case 5 patients
[0171]
[0172]
[0173] The patient's PT result was normal, but the APTT was significantly prolonged. A corrective test was needed to determine whether it was a lack of endogenous factors. The results are shown in Table 6.2.
[0174] Table 6.2 APTT correction test for case 5 patient
[0175]
[0176] Since PT was normal and the APTT correction test was able to completely correct the abnormal increase in APTT due to endogenous factor deficiency, we conducted a recalcification test on this sample plasma. We set the original APTT, 5min, 10min, 15min, 20min, and 30min incubation time gradients to obtain the recalcification test results in seconds at different incubation times, and made a recalcification test curve. The results are shown in the figure below. Figure 7 shown.
[0177] The recalcification test curve of the patient's plasma in Case 5 on ACL TOP 700 did not show the typical characteristics of a sharp drop, reaching the lowest point at 15 minutes, and then rising sharply.
[0178] The maximum seconds increase percentage rate and the maximum seconds decrease percentage rate of the recalcification test were calculated. The results are shown in Table 6.3.
[0179] Table 6.3 The percentage of decrease and increase in the maximum seconds in the recalcification test of case 5 patients
[0180] Maximum seconds drop percentage rate Maximum seconds increase percentage rate 5.6% 17.8%
[0181] Threshold A = 12.15% x 2 = 24.30%;
[0182] Threshold B = 10.05% x 3 = 30.15%;
[0183] Sequence comparison D1: 5.6% < 24.30%, judged as non-contact defect group. No need to continue sequence comparison D2.
[0184] It is judged to be a non-HMWK defect.
[0185] By measuring the activities of other coagulation factors in Case 5, it was found that the FIX activity was 0.9%, and the activities of other coagulation factors were normal. Case 5 patient had FIX deficiency.
[0186] Summarize
[0187] The present invention provides a method for detecting high molecular weight kininogen HMWK deficiency only for sample plasma without using deficient plasma. The method specifically performs a recalcification test on the sample plasma, sets different incubation time parameters, obtains a recalcification test curve with different incubation times as the horizontal coordinate and the recalcification test seconds as the vertical coordinate, obtains a unique recalcification test curve feature of HMWK deficiency, and according to the data analysis of the curve, the detection of HMWK deficiency can be achieved by using the recalcification test maximum seconds decrease percentage rate threshold A and the recalcification test maximum seconds increase percentage rate threshold B. The sample plasma of 5 patients was tested using the method of the present invention, and finally 2 cases of HMWK deficiency were detected. The detection method provided by the present invention is simple to operate, low in cost, and can quickly and accurately detect HMWK deficiency in sample plasma.
[0188] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes, characterized in that: The method comprises the following steps: (1) Automatically adding sample plasma into a reaction cup on a coagulation analysis instrument; (2) Add APTT reagent to the sample plasma, set different incubation times, and incubate them together at 37°C; (3) adding calcium chloride to trigger the coagulation process, and the time required for blood coagulation is used to obtain the number of seconds of the recalcification test under different incubation times; (4) The incubation time is taken as the horizontal axis and the number of seconds of the recalcification test is taken as the vertical axis to obtain the recalcification test curve; the test data are calculated and analyzed based on the curve.
2. The method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes according to claim 1, characterized in that: The different incubation times in step (2) are set to use the instrument manufacturer's parameters as the original incubation time, and then set the incubation time to 5 min, 10 min, 15 min, 20 min, and 30 min.
3. The method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes according to claim 1, characterized in that: The calculation and analysis method in step (4) is specifically to calculate the percentage rate of decrease in the maximum number of seconds in the recalcification test and the percentage rate of increase in the maximum number of seconds in the recalcification test.
4. The method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes according to claim 3, characterized in that: The percentage rate of decrease in the maximum number of seconds of the recalcification test = (the number of seconds of the APTT test result under the original incubation time - the minimum number of seconds of the recalcification test) / the number of seconds of the APTT test result under the original incubation time.
5. The method for detecting high molecular weight kininogen HMWK deficiency for non-disease diagnosis purposes according to claim 3, characterized in that: The percentage increase rate of the maximum number of seconds in the recalcification test = (the number of seconds in the recalcification test at an incubation time of 30 minutes - the minimum number of seconds in the recalcification test) / the minimum number of seconds in the recalcification test.
